Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.

Rubin, J; Ajani, J; Schirmer, W; Venook, A P; Bukowski, R; Pommier, R; Saltz, L; Dandona, P; Anthony, L

Rubin, J; Ajani, J; Schirmer, W; Venook, A P; Bukowski, R; Pommier, R; Saltz, L; Dandona, P; Anthony, L.

Affiliation

Rubin J; Mayo Clinic, Rochester, MN 55905, USA.

J Clin Oncol ; 17(2): 600-6, 1999 Feb.

Article in En | MEDLINE | ID: mdl-10080605

Subject(s)

Gastrointestinal Agents/administration & dosage; Malignant Carcinoid Syndrome/drug therapy; Octreotide/administration & dosage; Carcinoid Tumor/blood; Carcinoid Tumor/complications; Carcinoid Tumor/urine; Delayed-Action Preparations; Diarrhea/drug therapy; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Gastrointestinal Agents/blood; Humans; Hydroxyindoleacetic Acid/urine; Injections, Intramuscular; Injections, Subcutaneous; Male; Malignant Carcinoid Syndrome/blood; Malignant Carcinoid Syndrome/urine; Middle Aged; Octreotide/blood; Prospective Studies

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Gastrointestinal Agents / Octreotide / Malignant Carcinoid Syndrome Type of study: Clinical_trials / Observational_studies / Risk_factors_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: J Clin Oncol Year: 1999 Document type: Article Affiliation country: United States

Search on Google

Add to My VHL

XML

PubMed Links